Probiotics innocuous to salmonella vaccines

Commercial derivatives of specific strains of Saccharomyces cervisiae have the ability to agglutinate salmonella bearing Type-1 fimbriae in the intestinal tract of chickens. Laboratory evaluation of the four available licensed Salmonella Typhimurium mutant vaccines for poultry was performed to determine the effect of yeast cell-wall derivatives.
Applying the analytical method described by Mirelman developed in 1980, none of the four vaccines were affected by either Bio-Mos or Actigen. The test demonstrated that the two prebiotic products which have beneficial properties are compatible with administration and subsequent viability of the four U.S. licensed Salmonella Typhimurium mutant vaccines administered to protect the intestinal tract against colonization with Salmonella enteriditis and other serotypes.